Science Daily

Study finds statins reduce the relative risk of cardiovascular diseases by over 20% in adults aged 75+ with high cholesterol

Researchers provided comprehensive evidence of the benefits of statin use in elderly patients, addressing longstanding uncertainties. The robust evidence demonstrated that continuous statin therapy ...
Healio

Empagliflozin did not cut risk for death, HF hospitalization after heart attack: EMPACT-MI

Please provide your email address to receive an email when new articles are posted on . In patients with an acute MI, empagliflozin did not reduce risk for the primary endpoint of death or heart ...
EurekAlert!

HKUMed and Harvard world-first study finds statins reduce the relative risk of cardiovascular diseases by over 20% in adults aged 75+ with high cholesterol in Hong Kong

Researchers from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) and the Harvard TH Chan School of Public Health have provided the first comprehensive evidence of the benefits of ...
The American Journal of Managed Care

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Medscape

FDA Panel Recommends High-Dose EPA for CV Event Reduction

Icosapent ethyl (Vascepa, Amarin) was today unanimously recommended by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee for approval to reduce cardiovascular events as an adjunct to ...